This study looks at a treatment for a type of cancer called High-Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL), and similar conditions. The treatment uses a special drug, inotuzumab ozogamicin, which is a monoclonal antibody (a protein that can attach to cancer cells) linked to a chemotherapy drug called calicheamicin, to see if it helps patients do better. The study compares the use of this drug with regular cancer treatments. It also looks at how well patients follow their medicine plans and checks the effects on both boys and girls.
Key points:
- This study lasts up to 2 years with regular follow-up visits for up to 5 years.
- Participants will receive different types of chemotherapy, and some will get the new drug.
- There are risks like side effects from the drugs, and the study requires commitment to frequent medical visits.
How understandable was the trial content above?
Hard to understand
Easy to understand